Information for the public
Quizartinib (Vanflyta) is available on the NHS as a possible treatment for newly diagnosed FLT3‑ITD‑positive acute myeloid leukaemia in adults, when used:
- with standard cytarabine and anthracycline chemotherapy as induction treatment, then
- with standard cytarabine chemotherapy as consolidation treatment, then
- alone as maintenance treatment.
Induction treatment is the first stage of treatment; it is intensive chemotherapy that aims to remove the leukaemia cells in blood and bone marrow. Consolidation treatment aims to prevent the cancer coming back by removing any remaining leukaemia cells. Maintenance treatment aims to continue to prevent any leukaemia cells coming back.
Is this treatment right for me?
Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See our webpage on making decisions about your care.
Questions to think about
- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?
Information and support
The NHS webpage on acute myeloid leukaemia may be a good place to find out more.
These organisations can give you advice and support:
- Leukaemia Care, 08088 010 444
- Blood Cancer UK , 0808 2080 888
- Cancer Research UK, 0808 800 4040
- Macmillan Cancer Support, 0808 808 0000
You can also get support from your local Healthwatch.
NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.
ISBN: 978-1-4731-6530-4
This page was last updated: